GlassScriptPhysician profile
Magdy Elsakr
NPI 1184676785
$26,799.27
in general payments reported to CMS, 2019-2025
39 companies · $3,831 in 2025
The $3,831 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,436 · 2020: $2,001 · 2021: $2,467 · 2022: $3,705 · 2023: $3,815 · 2024: $3,544 · 2025: $3,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,087.75 |
| Education | $101.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,060.73 | 2019-2025 | |
| Abbvie INC. | $5,358.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,193.17 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $1,828.92 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $1,200.96 | 2019-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,151.81 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $1,059.79 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $753.41 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $726.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $693.58 | 2024-2025 | Omvoh, Mounjaro |
| Genzyme Corporation | $673.94 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $565.23 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $479.52 | 2019-2024 | Ocaliva |
| Braintree Laboratories, INC. | $397.19 | 2019-2025 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $351.21 | 2021-2023 | Zeposia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $331.70 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $314.81 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Aimmune Therapeutics, INC. | $289.16 | 2025 | Zenpep, Vowst |
| Celltrion USA INC. | $267.60 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Ipsen Biopharmaceuticals, INC | $263.97 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $249.86 | 2019-2024 | Dificid |
| Shionogi INC | $219.53 | 2019-2020 | |
| Boston Scientific Corporation | $182.19 | 2023-2025 | Exalt Model D, Spyglass, General - Biopsy |
| Regeneron Healthcare Solutions, INC. | $169.42 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $141.85 | 2024 | Voquezna |
| Dova Pharmaceuticals | $121.16 | 2019 | |
| Allergan, INC. | $110.09 | 2019 | |
| Janssen Scientific Affairs, LLC | $100.07 | 2019 | |
| Qol Medical, LLC | $81.94 | 2019-2025 | Sucraid |
| Biocon Biologics INC | $65.17 | 2024-2025 | Hulio, Yesintek |
| Novo Nordisk INC | $63.76 | 2025 | Wegovy |
| Advanced Accelerator Applications | $56.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.25 | 2023-2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $48.16 | 2020 | |
| Organon LLC | $38.99 | 2023-2024 | Renflexis |
| Daiichi Sankyo INC. | $38.76 | 2021 | |
| Omega Medical Imaging, LLC | $32.55 | 2025 | |
| Shire North American Group INC | $32.49 | 2019 | |
| Ethicon US, LLC | $30.44 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdy Elsakr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.